A Pilot Study of Acalabrutinib With Bendamustine/Rituximab Followed by Cytarabine/Rituximab for Untreated Mantle Cell Lymphoma

被引：0
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 04期
关键词：
TRIAL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [41] Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience
    Logothetis, Constantine N.
    Horvat, Nathan P.
    Kurian, Tony
    Bello, Celeste
    Chavez, Julio
    Isenalumhe, Leidy
    Shah, Bijal
    Sokol, Lubomir
    Saeed, Hayder
    Pinilla, Javier
    Gaballa, Sameh
    ONCOLOGY RESEARCH, 2024, 32 (06) : 1031 - 1036
  • [42] Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
    Tisi, Maria Chiara
    Moia, Riccardo
    Patti, Caterina
    Evangelista, Andrea
    Ferrero, Simone
    Spina, Michele
    Tani, Monica
    Botto, Barbara
    Celli, Melania
    Puccini, Benedetta
    Cencini, Emanuele
    Di Rocco, Alice
    Chini, Claudio
    Ghiggi, Chiara
    Zambello, Renato
    Zanni, Manuela
    Sciarra, Roberta
    Bruna, Riccardo
    Ferrante, Martina
    Pileri, Stefano Alessandro
    Quaglia, Francesca Maria
    Stelitano, Caterina
    Re, Alessandro
    Volpetti, Stefano
    Zilioli, Vittorio Ruggero
    Arcari, Annalisa
    Merli, Francesco
    Visco, Carlo
    BLOOD ADVANCES, 2023, 7 (15) : 3916 - 3924
  • [43] Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
    Dennie, Trevor W.
    Kolesar, Jill M.
    CLINICAL THERAPEUTICS, 2009, 31 : 2290 - 2311
  • [44] Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)
    Kiesewetter, Barbara
    Mayerhoefer, Marius E.
    Lukas, Julius
    Zielinski, Christoph C.
    Muellauer, Leonhard
    Raderer, Markus
    ANNALS OF HEMATOLOGY, 2014, 93 (02) : 249 - 253
  • [45] Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma
    Samaniego, Felipe
    McLaughlin, Peter
    Neelapu, Sattva S.
    Feng, Lei
    Fanale, Michelle
    Nastoupil, Loretta
    Rodriguez, Maria Alma
    Pro, Barbara
    Taylor, Erin
    Hagemeister, Fredrick B.
    Fowler, Nathan
    LEUKEMIA & LYMPHOMA, 2021, 62 (01) : 58 - 67
  • [46] Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
    Vitolo, Umberto
    Trneny, Marek
    Belada, David
    Burke, John M.
    Carella, Angelo Michele
    Chua, Neil
    Abrisqueta, Pau
    Demeter, Judit
    Flinn, Ian
    Hong, Xiaonan
    Kim, Won Seog
    Pinto, Antonio
    Shi, Yuan-Kai
    Tatsumi, Yoichi
    Oestergaard, Mikkel Z.
    Wenger, Michael
    Fingerle-Rowson, Gunter
    Catalani, Olivier
    Nielsen, Tina
    Martelli, Maurizio
    Sehn, Laurie H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31) : 3529 - +
  • [47] Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era
    Karmali, Reem
    Switchenko, Jeffrey M.
    Goyal, Subir
    Shanmugasundaram, Krithika
    Churnetski, Michael C.
    Kolla, Bhaskar
    Bachanova, Veronika
    Gerson, James N.
    Barta, Stefan K.
    Gordon, Max J.
    Danilov, Alexey, V
    Grover, Natalie S.
    Epperla, Narendranath
    Mathews, Stephanie
    Burkart, Madelyn
    Sawalha, Yazeed
    Hill, Brian T.
    Ghosh, Nilanjan
    Park, Steven, I
    Bond, David A.
    Maddocks, Kami J.
    Badar, Talha
    Fenske, Timothy S.
    Hamadani, Mehdi
    Guo, Jin
    Malecek, Mary
    Kahl, Brad S.
    Martin, Peter
    Blum, Kristie A.
    Flowers, Christopher R.
    Cohen, Jonathon B.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (11) : 1374 - 1384
  • [48] Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma
    Karmali, Reem
    Larson, Melissa L.
    Wooldridge, James E.
    Gregory, Stephanie A.
    O'Brien, Teresa
    Shammo, Jamile M.
    Bueschel, Katherine
    Venugopal, Parameswaran
    LEUKEMIA & LYMPHOMA, 2011, 52 (11) : 2097 - 2104
  • [49] Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study
    Houillier, Caroline
    Ghesquieres, Herve
    Chabrot, Cecile
    Soussain, Carole
    Ahle, Guido
    Choquet, Sylvain
    Nicolas-Virelizier, Emmanuelle
    Bay, Jacques-Olivier
    Vargaftig, Jacques
    Gaultier, Claude
    Touitou, Valerie
    Martin-Duverneuil, Nadine
    Cassoux, Nathalie
    Le Garff-Tavernier, Magali
    Costopoulos, Myrto
    Faurie, Pierre
    Hoang-Xuan, Khe
    JOURNAL OF NEURO-ONCOLOGY, 2017, 133 (02) : 315 - 320
  • [50] Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
    Sun, Xuefei
    Liu, Jing
    Wang, Yaming
    Bai, Xueyan
    Chen, Yuedan
    Qian, Jun
    Zhu, Hong
    Liu, Fusheng
    Qiu, Xiaoguang
    Sun, Shengjun
    Ji, Nan
    Liu, Yuanbo
    ONCOTARGET, 2017, 8 (30) : 49156 - 49164
12345